Active Filter(s):
Details:
Proceeds will be used to advance Vita’s lead pre-clinical program VTA-100 for limb-girdle muscular dystrophy (LGMD2A) to the clinic. It will also fund the development of Vita’s newest program, VTA-120 for the treatment of patients with facioscapulohumeral muscular dystrophy.
Lead Product(s): VTA-100
Therapeutic Area: Genetic Disease Product Name: VTA-100
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cambrian BioPharma
Deal Size: $31.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 12, 2022